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INTRODUCTION
Osteoclasts are multinucleated cells specialized in bone resorption. Upon the differentiation process stimulated by the cytokine RANKL, osteoclasts activate a complex transcriptional program (1) while they undergo profound actin cytoskeleton reorganization (2, 3). Osteoclasts anchor to the bone matrix through the sealing zone, a dynamic actin ring that delineates the resorption lacuna (4). The importance of actin-based structures in osteoclast function suggests an essential role for RhoGTPases in these cells. Through the control of actin dynamics, small GTPases of the Rho family regulate many cellular processes such as cell adhesion, migration and morphology (5) as well as vesicular trafficking (6, 7) . RhoGTPases cycle between an inactive GDP-and an active GTP-bound state. The Rho family of small GTPases comprises 18 members involved in actin cytoskeleton reorganization (8), namely RhoA, B and C, Rac1, 2 and 3, RhoG, Cdc42, RhoQ/TC10, RhoJ/TCL, RhoV/Chp1, RhoU/Wrch1, Rnd1, RhoN/Rnd2, RhoE/Rnd3, RhoD, RhoH and RhoF/Rif. In the cell, RhoGTPases are activated by Guanine nucleotide Exchange Factors (RhoGEFs) that catalyze the exchange of GDP for GTP (9) . There are more than 70 RhoGEFs in mammals, that belong to two families: over 60 Dblrelated proteins (9) and 11 DOCK-related CZH proteins (10). Different studies highlighted the importance of RhoGTPases in cell differentiation, including the development of the nervous system (11) and B-cell maturation (12). RhoGTPases are also essential for skeletal muscle and trophoblast differentiation (13, 14) . Interestingly, myoblasts, trophoblasts and osteoclasts are the only cell types that undergo cell fusion during normal differentiation. Since the cell fusion process implies important actin cytoskeleton remodeling and involves RhoGTPases in myoblasts and trophoblasts differentiation (15) (16) (17) , it suggests that Rho signaling pathways could also control the fusion of osteoclast precursors.
Only few RhoGTPases and RhoGEFs have been studied in osteoclasts. Several studies reported the role of RhoA, Rac1, Rac2 and Cdc42 in the control of osteoclast resorbing activity or adhesion to the bone matrix (4, (18) (19) (20) (21) (22) (23) . Moreover, farnesyl pyrophosphate synthase is the specific target of nitrogen-containing bisphosphonates, the most widely used treatement for osteoporosis. Interestingly, this enzyme is essential for the prenylation and thereby the activity of RhoGTPases such as RhoA, Rac1 and Cdc42 (24) . Bisphosphonate treatment results in the loss of osteoclast activity and induction of apoptosis, possibly through the inactivation of RhoGTPases (25).
The RhoGEF Vav3 is also required for the osteoclastic bone matrix degradation (26).
Despite the clear implication of RhoGTPase signaling pathways in osteoclast biology, no information is available on the role of most RhoGTPases and RhoGEFs during osteoclast differentiation and bone resorption.
In this study, we established the expression profile of RhoGTPases and RhoGEFs using Affymetrix DNA micro 4 arrays and real-time quantitative PCR during osteoclast differentiation. We performed differentiation in vitro using RAW264.7 cells and ex vivo using bone marrow macrophages and hematopoietic stem cells as osteoclast precursors. We identified three genes up-regulated by RANKL and further demonstrate they are essential in osteoclasts using small hairpin RNAs (shRNAs) to inhibit their expression.
MATERIALS AND METHODS

Cells and microscopy analyses.
Cells were cultured in a humidified incubator (5% CO 2 in air) at 37°C. NIH3T3 mouse fibroblastic and 293T human embryonic kidney cell lines were cultured in the following growth medium: DMEM containing 10% fetal calf serum (Hyclone) with 2 mM glutamine. Mouse monocytic RAW264.7 cells (a gift from P. Jurdic, Lyon, France) and bone marrow-derived cells were grown in the following growth medium: alpha-MEM containing 10% heat-inactivated fetal calf serum (Hyclone) with 2 mM glutamine. For osteoclast differentiation, RAW264.7 cells were seeded at 5x10 4 cells per well in a 6-well plate with 25 ng/ml of RANKL (Peprotech).
Medium was changed every second day.
Bone marrow was collected from 4-5 week old C57BL/6 mice. Lin-CD117+ hematopoietic stem cells (HSCs) (27) were isolated from total bone marrow by depletion of differentiated cells (CD5+, CD45R+, CD11b+, Ly-6G+, 7-4+ and Ter-119+) with antibody-coupled magnetic beads using the cell lineage depletion kit provided by Miltenyi Biotec (Bergisch Gladbach, Germany) on a MACS separator system, followed by positive selection of CD117+ cells with Miltenyi Biotec anti-CD117 coupled magnetic beads. To purify Bone
Marrow Macrophages (BMMs), non-adherent cells from total bone marrow (2.5x10 6 per well in a 6-well plate)
were cultured with 50 ng/ml M-CSF (Peprotech) for 48 hours. Adherent cells were used as BMMs after washing non-adherent cells. Lin-CD117+ hematopoietic stem cells (HSCs) and adherent Bone Marrow Macrophages (BMMs) were used as osteoclast precursors. For osteoclast differentiation, HSCs and BMMs were further cultured in the presence of 50 ng/ml M-CSF and 100 ng/ml RANKL. Medium was changed every second day.
After fixation in 10% formalin for 10 minutes and washing with ethanol-acetone (1:1 volume-volume), osteoclast differentiation was assessed by staining for the tartrate-resistant acid phosphatase (TRAP), a marker enzyme for osteoclasts, with 0.1 mg/ml naphtol AS-MX phosphate and 0.6 mg/ml fast red violet LB salt in 0.1 M sodium acetate buffer pH 5 containing 50 mM sodium tartrate. Nuclei were stained with Hoechst dye and actin with rhodamine-labeled phalloidin (Sigma Aldrich). Cells were observed using a DMR B microscope (Leica Microsystems). Images were captured with a MicroMax 1300 HS (B/W) cooled charge coupled device camera or CoolSnap Color Camera (Roper Scientific) using a MetaMorph control program (Princeton Scientific Instruments). TRAP-positive cells with more than 3 nuclei were considered as osteoclasts. The frequency of osteoclast formation was calculated as the fusion index according to the formula: Fusion Index (%)=(number of nuclei in multinucleated cells)x100/(total number of nuclei). In each of three independent experiments and for each shRNA, the fusion indexes were determined in 12 to 15 microscopic fields of 0.6 mm 2 , counting a total of 6 at least 2500 nuclei. Statistical analyses were performed by analysis of variance (ANOVA), using Fisher's Least Significant Difference (LSD) procedure to discriminate among means. Differences were considered significant for P<0.05. For the same shRNA, the mean fusion indexes did not vary significantly between experiments (P>5%) whereas the shRNA type correlated significantly with the fusion index (P=0.0002).
Real-time PCR analyses
DNaseI-treated total RNAs were extracted using the High Pure RNA Isolation kit (Roche Diagnostics).
To generate cDNA, RNA was primed with 10-mer random primers and reverse transcription catalyzed using Superscript II reverse transcriptase (Invitrogen). Quantitative PCR was performed with a Light Cycler (Roche Diagnostics) or an Mx3000p PCR system (Stratagene) using the Platinium Taq DNA polymerase (Invitrogen) and SYBR Green I (Bio Wittaker) as described (28). All primer pairs used in this study are listed in Table 1 . For each primer set, specificity was assessed by purification and sequencing of the PCR product. All real time PCR measures to quantify cDNAs were done in triplicate and the 95% confidence limits of the ratios to Gapdh were determined by Student's t-test. In each experiment, cDNA levels were considered changing between the two conditions tested (with and without RANKL) when the 95% confidence limits of their ratios to Gapdh were not overlapping. All genes tested consistently gave the same results (changing or not changing,) in the three experiments. Data shown are representative of one experiment. The values of the cDNA ratios to Gapdh are not intended to be compared from one gene to another.
Gene Array Studies.
Total RNA from RANKL-treated and control RAW264.7 cells was prepared using the guanidium thiocyanate technique as described previously (29). Total RNA quality was ascertained using the Agilent Bioanalyser 2100 using the NanoChip protocol. Total RNA was labeled using the Affymetrix One Cycle cRNA synthesis kit (Millenium Sciences) and cleaned using the Affymetrix GeneChip Sample Cleanup kit (Millenium Sciences). Resultant cRNA was labeled with biotin using the Affymetrix IVT labeling kit (Millenium Sciences) and cleaned using the above Cleanup kit. A total of 20 µg of labeled cRNA was then fragmented to the 50-200 base pair size range and quality control checked with the Agilent Bioanalyser 2100 using the NanoChip protocol.
For hybridization of the Mouse 430 version 2.0 GeneChip, cRNA was included at 0.05 g/l in 1x Hybridization
Buffer (100 mM MES, 1m NaCl, 20 mM EDTA, 0.01% Tween-20), 0.1 mg/ml Herring Sperm DNA, 0.5 mg/ml BSA, and 7% DMSO. Hybridization was performed at 45°C for 16 hours in an oven with a rotating wheel. After hybridization, chips were washed using the appropriate fluidics script in the Affymetrix Fluidics Station 450 and 7 scanned using the Affymetrix GeneChip Scanner 3000. Scanned output files were analyzed using Micro Array Suite software (Affymetrix).
Western blot analyses.
Polyclonal antiserum against Arhgef8/Net1 was from Santa Cruz Biotechnology. Polyclonal anti-Gapdh antibody was described earlier (7). Horseradish peroxidase-conjugated secondary antibodies were from Amersham Bioscience and detected using enhanced chemiluminescence from Perkin Elmer Life Science.
RAW264.7 whole cell extracts were prepared in Laemmli sample buffer, resolved on SDS-PAGE and electrotransferred on nitrocellulose membranes. Immunoblotting was then performed according to manufacturer instructions.
Small hairpin RNA retroviral vector construction and RAW264.7 cell infection.
19 mer small hairpin RNA (shRNA) target sequences (Wr-1, Wr-2, Gef8-1, Gef8-2, Dk5-1 and Dk5-2, 
RESULTS
RhoGTPase expression profiles during osteoclast differentiation.
To identify RhoGTPases genes up-regulated during RANKL-induced osteoclastogenesis, we designed 18 primer sets to amplify each RhoGTPase (Table 1) . For all primer sets chosen for this study, the PCR efficiency was above 95% (not shown). As Rho family members can have up to 70% identity at the nucleic acid level, primers where chosen in the most divergent regions and specificity was verified by sequencing the PCR products. These primers were then used to quantify RhoGTPase mRNAs during osteoclast differentiation of RANKL-treated RAW264.7 cells. For each sample, Gapdh was used as an internal house keeping gene control. RhoGTPases, namely Rac2, RhoA, RhoB, RhoC, RhoG, Cdc42, RhoF/Rif, Rac1, RhoQ/TC10, Rnd1, RhoN/Rnd2 and RhoV/Chp1, we did not observe any significant variation of mRNA levels during osteoclast differentiation (Fig. 1B) . Finally, the mRNAs of 5 GTPases were not detected: RhoD, RhoH, Rac3, RhoJ/TCL and RhoE/Rnd3 (not shown).
These results show that Wrch1 gene expression is strongly up-regulated during osteoclastogenesis stimulated by RANKL in RAW264.7 cells; 5 RhoGTPases are not expressed and mRNA levels of 12
RhoGTPases are not affected by RANKL treatment in RAW264.7 cells.
RhoGEF expression profiles during osteoclast differentiation.
In cells, RhoGTPases are activated by guanine nucleotide exchange factors. We thus explored the expression of RhoGEFs during osteoclast differentiation. As the mouse genome contains 65 Dbl related and 11
DOCK related RhoGEF genes, we performed DNA micro array analyses to examine their expression during osteoclast differentiation. We identified probe sets for the 76 mouse RhoGEFs in the mouse genome A430-2
Affymetrix oligonucleotide chip (Table 2) . BLAST searches were performed on each probe set through In agreement with earlier reports, we detected the up-regulation of known RANKL-induced genes, such as TRAP, Cathepsin K, Src and MMP-9 (Table 3) . Moreover and consistent with the above RT-PCR studies, we observed a strong up-regulation of Wrch1 in RANKL-treated RAW264.7 cells (Table 3) , while the RhoGTPases TCL, RhoD, RhoH, Rnd3 and Rac3 were absent (not shown). These results warranted our analysis. Since ß-actin and Gapdh control house keeping genes showed a 1.4 to 1.6 fold increase respectively in cells treated with RANKL, we chose to define as RANKL-induced RhoGEFs those with over 3 fold up-regulation in RANKLtreated as compared to control cells. Of the 76 RhoGEFs, 42 RhoGEFs were expressed and 34 genes were not (Table 2) , based on the absolute calls determined by Micro Array Suite software provided by Affymetrix for data analysis. Of the 42 RhoGEF genes expressed, 7 genes were up-regulated in RANKL-treated cells: Dock5, Fgd6, Geft, Farp2, Vav3, Arhegf8/Net1 and Arhgef12/Larg (Table 4) .
To confirm the DNA micro array analyses, we designed primer sets to amplify and quantify the 7
RhoGEFs identified above (Table 1) . Itsn2 was used as a control as its expression is not modified in RANKLtreated cells (Table 4 ). The specificity of the primers was verified by sequencing the PCR products and PCR efficiency was above 95% for all primer sets (not shown). Real-time PCR analyses confirmed that the 7
RhoGEFs identified by DNA micro arrays were up-regulated during osteoclastogenesis induced by RANKL in RAW264.7 cells (Fig. 1D ). Also expected from the DNA chip experiment, the level of Itsn2 did not vary significantly between RANKL-treated and -untreated cells (Table 4 and Fig. 1D ). We also verified the induction of Src, TRAP (not shown) and Wrch1 (Fig. 1D ). Western blot analyses in RAW264.7 showed that Arhgef8 protein expression is induced by RANKL (Fig. 1E ).
By combining gene array and real-time PCR analyses, we show here that 7 out of the 76 mouse RhoGEFs genes are up-regulated during osteoclast differentiation induced by RANKL in RAW264.7 cells.
RANKL-dependent induction of Wrch1 and RhoGEFs in osteoclasts differentiated ex vivo.
To extend the results obtained in RAW264.7 cell line, we differentiated osteoclasts ex vivo using two types of precursor cells isolated from mouse bone marrow: lin-CD117+ hematopoietic stem cells (HSCs) or bone marrow macrophages (BMMs). Multinucleated TRAP positive cells appeared at day 5 to 6 after RANKL addition in BMM cultures and at day 6 to 7 after RANKL addition in HSC cultures (shown for HSCs in Fig. 2A and B). Osteoclast differentiation was monitored by the increase in Src and TRAP mRNAs levels, as determined by real-time PCR (shown for HSCs in Fig. 2C ).
We observed the up-regulation of Wrch1 gene expression during HSC and BMM osteoclastogenesis while the level of Cdc42 did not change significantly (Fig. 2D for HSCs and 2E for BMMs). Arhgef8 and Dock5
were also up-regulated during osteoclastogenesis in both ex vivo differentiation systems ( Fig. 2F and G) . By contrast, Arhgef12, Farp2 and Fgd6 genes that were significantly up-regulated in RANKL-treated HSCs (Fig.   2F ) did not vary significantly in BMMs (Fig. 2G ). The expression of Vav3 was not significantly modified by RANKL treatment in HSCs and BMMs ( Fig. 2F and G) . Finally, Geft was not detected in HSCs and BMMs treated with M-CSF alone or M-CSF and RANKL (not shown) whereas it was expressed in RAW264.7 cells (Fig. 1D and Table 4 ).
These results obtained with HSCs and BMMs, two types of bone marrow-derived osteoclast precursors, confirmed that the RhoGTPase Wrch1 and the RhoGEFs Arhgef8 and Dock5 are up-regulated during RANKLinduced osteoclastogenesis.
Wrch1, Arhgef8 and Dock5 silencing affects osteoclast differentiation.
To test the importance of Wrch1, Arhgef8 and Dock5 in osteoclasts, we performed small hairpin RNAinduced gene silencing. We selected 2 target sequences in the open reading frames of each gene (Fig. 3A) and generated small hairpin RNA expression vectors. Firefly Luciferase specific shRNA was used as control ( gene expression throughout osteoclast differentiation (Fig. 3B ) and so did Gef8-1 and Gef8-2 toward Arhgef8 (Fig. 3C) . To evaluate the effect of Wrch1 and Arhgef8 gene silencing on osteoclast differentiation, RAW264.7
expressing the different shRNAs were fixed after 5 days of exposition to RANKL, stained for TRAP and DNA and the fusion indexes were determined as described in Materials and Methods. Wrch1 and Arhgef8 silencing led to a strong diminution of the fusion indexes (Fig. 3D) . The average fusion index was 13.6 ± 0.6 % in
Luciferase shRNA-expressing cells, it dropped down to 2.9 ± 0.8 % and 4 ± 0.9 % in Wr-1 and Wr-2 shRNAexpressing cells respectively, and down to 6.0 ± 1.2 % and 6.5 ± 1.4 % in Gef8-1 and Gef8-2 shRNAexpressing cells respectively. Osteoclasts expressing Luciferase shRNA did not show any morphological changes as compared to control uninfected cells ( Fig. 3E and F) . By contrast, osteoclasts differentiated from Wrch1 or Arhgef8 shRNA-expressing cells were abnornally spread and had long peripheral extensions (Shown 11 for Wr-1 and Gef8-2 in Fig. 3G and H). Contrarily to Wrch1 and Arhgef8, Dock5 silencing was highly toxic in RAW264.7. Cells expressing Dk5-1 and Dk5-2 died massively within 3 days after infection (not shown), therefore further studies could not be performed in these cells. To assay for cell type specificity of Dock5 silencing cytotoxic effect, Dk5-1 and Dk5-2 were expressed in NIH3T3 fibroblastic cells. Dock5 was efficiently silenced by Dk5-1 and Dk5-2 as shown by quantitative RT-PCR (Fig. 3I ). Interestingly and in contrast with RAW264.7 cells, Dock5 silencing was not cytotoxic in NIH3T3 and cells did not show any noticeable changes in actin structure as compared to control Luciferase shRNA expressing cells (shown for Dk5-2 in Fig. 3J and K) .
These results show that Dock5 is essential in RAW264.7 cells and that it is not an essential house-keeping gene as its silencing has no effect in NIH3T3 fibroblastic cells.
These results show that the three genes that we identified and that are up-regulated during RANKLstimulated osteoclastogenesis are essential in osteoclasts: Wrch1 and Arhgef8 silencing inhibited cell fusion and Dock5 silencing was cytotoxic in RAW264.7 monocytic cells, while having no effect in fibroblasts.
DISCUSSION
In this report, we studied the expression of 18 low molecular weight 
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1435244_at NM_009500 P P Vav3 1417123_at NM_020505 P P P, present; A, Absent; Accession no., GenBank accesion number; +RANKL, RAW264.7 cells treated with RANKL for 72 hours; -RANKL, control RAW264.7 cells; Probe set, Affymetrix coordinates. 
